)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Boundless Bio (BOLD) investor relations material
Boundless Bio Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary5 Nov, 2025
Executive summary
Focused on developing ecDNA-directed therapeutics (ecDTx) for oncogene-amplified cancers, with BBI-355/BBI-825 in Phase 1/2 and BBI-940 in preclinical development; enrollment is ongoing in the BBI-355/BBI-825 combination arm of the POTENTIATE trial.
IND submission for BBI-940 is on track, with a first-in-human clinical trial expected in the first half of 2026.
Discontinued certain trial arms and streamlined operations, including a workforce reduction, to extend cash runway and prioritize key programs.
Cash position of $117.6 million as of September 30, 2025, supports operations into the first half of 2028, covering expected proof-of-concept readouts for both programs.
No product revenue to date; expects continued operating losses and need for additional capital before commercialization.
Financial highlights
Cash, cash equivalents, and short-term investments totaled $117.6 million as of September 30, 2025.
Net loss was $13.9 million for Q3 2025 (vs. $16.5 million Q3 2024) and $45.3 million for the nine months ended September 30, 2025 (vs. $48.9 million prior year period).
R&D expenses decreased to $10.7 million in Q3 2025 (from $14.1 million Q3 2024) and $35.0 million for the nine months (from $42.0 million prior year).
G&A expenses were $4.5 million in Q3 2025 (vs. $4.6 million Q3 2024) and $14.5 million for the nine months (vs. $13.0 million prior year).
Net loss per share was $(0.62) for Q3 2025 and $(2.03) for the nine months ended September 30, 2025.
Outlook and guidance
Current cash runway expected to fund operations into the first half of 2028, based on current plans and assumptions.
Initial proof-of-concept data for BBI-355/BBI-825 and BBI-940 expected within existing cash runway.
IND application for BBI-940 and initiation of Phase 1 trial anticipated in the first half of 2026.
Substantial additional funding will be required to complete development and commercialization of ecDTx.
Q3 R&D expense reduction drivers
Assumptions for H1 2028 cash runway?
BBI-355/BBI-825 overlapping toxicity risk?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Boundless Bio earnings date
Q4 20256 Mar, 2026
Next Boundless Bio earnings date
Q4 20256 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Boundless Bio Inc., trading under the NASDAQ symbol BOLD, is a clinical-stage oncology company focused on developing novel cancer treatments. The company leverages its proprietary Spyglass platform to target extrachromosomal DNA (ecDNA), which plays a significant role in oncogene amplification in over 14% of cancer patients. By identifying and inhibiting targets essential for ecDNA functionality, Boundless Bio aims to develop ecDNA-directed therapeutic candidates (ecDTx) designed to selectively eliminate cancer cells containing ecDNA without harming healthy cells. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage